![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » TANABE SEIYAKU, CENTOCOR IN AGREEMENT FOR GOLIMUMAB
TANABE SEIYAKU, CENTOCOR IN AGREEMENT FOR GOLIMUMAB
August 24, 2006
Tanabe Seiyaku Co. Ltd. and Centocor Inc., Pennsylvania, USA, a division of Johnson & Johnson (J&J) Group concluded an agreement on co-development and co-marketing of the anti TNFa monoclonal antibody, CNTO 148 (Golimumab), of Centocor in Japan, Taiwan and Indonesia. BioSpectrum (http://www.biospectrumasia.com/content/230806JPN1418.asp)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct